| Variables |
Data |
Nd |
| Biodemographic Data |
|
|
| Age, years |
67.5 ± 13.4 |
227/227 |
| Women |
52.0% |
118/227 |
| Ethnics:Caucasian |
83.3 % |
189/227 |
| Non Caucasian |
16.7 % |
38/227 |
| Diseases |
|
|
| Arterial Hypertensiona |
70.9% |
158/223 |
| Atrial Fibrillationc |
69.1% |
154/223 |
| CardiacFailurea |
39.5% |
88/223 |
| Dyslipidemiab |
35.9% |
80/223 |
| Obesitya |
13.5% |
30/223 |
| Acute myocardial infarctionc |
11.2% |
25/223 |
| Hypothyroidismb |
11.2% |
25/223 |
| Strokea |
7.6% |
17/223 |
| Chronic Renal Failurea |
4.0% |
09/223 |
| NephroticSyndromea |
0.5% |
01/223 |
| Other Diseases non related with INRc |
98.6% |
220/223 |
| Concomitantmedicationsd |
|
|
| INR increase |
72.2% |
161/223 |
| INR decrease |
28.7% |
64/223 |
| Increase and/or decrease INR |
3.1% |
07/223 |
| Withoutinfluenceon INR |
94.2% |
210/223 |
| Average of number of medications used |
4.4 ± 2.6 |
223 |
| Target INR Range (2.0-3.0)e |
78.0% |
177/227 |
| Weekly dose warfarin, mg |
25.4 ±12.8 |
227 |
aComorbidities that increase INR. bComorbidities that decrease INR. cComorbidities
without clinical influence. dData from 4 patients are missing. eTarget INR range
for mechanical valves and recurring systemic embolism is 2.5-3.5 and for other
indications is 2.0-3.0 (29). INR: International Normalization Ratio; N: Number of
Patients.
|
